Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 164-172

  Gout, Olivier ^a   Bouchareine, Annie ^a   Moulignier, Antoine ^a   Deschamps, Romain ^a   Papeix, Caroline ^a   Gorochov, Guy ^b,c,d   Héran, Françoise ^a   Bastuji Garin, Sylvie ^e,f  

^a Department of Neurology Fondation Ophtalmologique A de Rothschild ^*  (France)

^b Laboratory of Immunology AP   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

clinically isolated syndrome; CSF; MRI; multiple sclerosis

Indexed keywords

CORTICOSTEROID; GADOLINIUM PENTETATE; METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; SCORING SYSTEM;

EID: 79951543343     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510385506     Document Type: Article

References (24)

1. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231. (Pubitemid 13158528)
2. Barkhof F., Filippi M., Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997 ; 120: 2059-2069. (Pubitemid 27493740)
3. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
4. Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 2005 ; 58: 840-846. (Pubitemid 41746873)
5. Korteweg T., Tintoré M., Uitdehaag B., et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicenter follow-up study. Lancet Neurol 2006 ; 5: 221-227. (Pubitemid 43238345)
6. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452. (Pubitemid 14237132)
7. Keir G., Luxton RW and Thompson EJ Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 1990 ; 27: 436-443. (Pubitemid 20340288)
8. Reiber H. Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 1998 ; 4: 99-107. (Pubitemid 28410032)
9. Freedman MS, Thompson EJ, Deisenheimer F., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. A consensus statement. Arch Neurol 2005 ; 62: 865-870. (Pubitemid 40973448)
10. Andersson M., Alvarez-Cermeno J., Bernardi G., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994 ; 57: 897-902. (Pubitemid 24251050)
11. Tintoré M., Rovira A., Río J., et al. New diagnostic criteria for multiple sclerosis application in first demyelinating episode. Neurology 2003 ; 60: 27-30. (Pubitemid 36070639)
12. Dalton CM, Brex P., Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002 ; 52: 47-53. (Pubitemid 34693742)
13. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997 ; 49: 1404-1413.
14. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 2003 ; 121: 944-949.
15. Barkhof F., Rocca M., Francis G., et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon 1a. Ann Neurol 2003 ; 53: 718-724. (Pubitemid 36622508)
16. Kappos L., Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 2006 ; 67: 1242-1249. (Pubitemid 44563835)
17. Söderström M., Ya- Ping J., Hillert J. and Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF and HLA findings. Neurology 1998 ; 50: 708-714.
18. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997 ; 41: 392-398. (Pubitemid 27114051)
19. Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996 ; 46: 368-372. (Pubitemid 26081315)
20. Tintoré M., Rovira A., Río J., et al. Do oligoclonal bands add information to MRI in first attack of multiple sclerosis? Neurology 2008 ; 70: 1079-1083. (Pubitemid 351464763)
21. Zipoli V., Hakiki B., Portaccio E., et al. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler 2009 ; 15: 472-478.
22. Rudick RA, Cookfair DL, Simonian NA, et al. Cerebrospinal fluid abnormalities in phase III trial of Avonex (INFbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999 ; 93: 8-14. (Pubitemid 29051546)
23. Sellebjerg F., Christiansen M., Nielsen PM and Frederiksen JL Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler 1998 ; 4: 475-479. (Pubitemid 29042153)
24. Siritho S. and Freedman MS The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009 ; 279: 21-25.